Background: Currently, the axillary management strategy of omitting axillary lymph node dissection (ALND) in early-stage breast cancer (BC) patients with cT1-2, clinically node-negative (cN0), and ...

The Gazette offers audio versions of articles using Instaread. Some words may be mispronounced. This story first appeared in Healthy You - July 2025, The Gazette’s quarterly health publication. Lymph ...

Dr. Rita Mukhtar and Dr. Joshua K. Sabari discuss the role of ctDNA to guide surgical decision-making after neoadjuvant chemo in breast cancer treatment. Dr. Rita Mukhtar and Dr. Joshua K. Sabari sat ...

ABSTRACT: Background: Sentinel lymph node (SLN) biopsy remains a cornerstone in the management of breast cancer, as it provides an accurate staging of the disease while minimizing the morbidity ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Sentinel lymph node biopsy has replaced traditional axillary dissection, minimizing lymphedema risk in breast cancer surgery. The procedure targets the first draining lymph nodes, reducing unnecessary ...

Background: Sentinel lymph node biopsy (SLNB) has become standard procedure for early breast cancer patients with clinically node negative disease. The patients with SLN metastasis normally underwent ...

Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast ...

Trends and outcomes in patients receiving neoadjuvant chemotherapy for breast cancer in Ontario: A population-based study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...